Vfend is a drug owned by Pf Prism Cv. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 29, 2022. Details of Vfend's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6632803 | Pharmaceutical formulations containing voriconazole |
Jun, 2018
(6 years ago) |
Expired
|
| US5567817 | Triazole antifungal agents |
May, 2016
(8 years ago) |
Expired
|
FDA has granted several exclusivities to Vfend. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Vfend, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Vfend.
Exclusivity Information
Vfend holds 1 exclusivities. All of its exclusivities have expired in 2022. Details of Vfend's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jan 29, 2022 |
US patents provide insights into the exclusivity only within the United States, but Vfend is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Vfend's family patents as well as insights into ongoing legal events on those patents.
Vfend's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Vfend's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jan 29, 2022 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Vfend Generic API suppliers:
Voriconazole is the generic name for the brand Vfend. 23 different companies have already filed for the generic of Vfend, with Rising having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Vfend's generic
How can I launch a generic of Vfend before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Vfend's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Vfend's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Vfend -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 200 mg/vial | 12 Sep, 2008 | 1 | 30 May, 2012 | 02 Jun, 2018 | Eligible |
| 40 mg/mL | 08 Oct, 2010 | 1 | 28 May, 2013 | 24 May, 2016 | Eligible |
| 50 mg and 200 mg | 14 Apr, 2008 | 1 | 22 Apr, 2010 | 24 May, 2016 | Eligible |
Alternative Brands for Vfend
Vfend which is used for treating fungal infections., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
About Vfend
Vfend is a drug owned by Pf Prism Cv. It is used for treating fungal infections. Vfend uses Voriconazole as an active ingredient. Vfend was launched by Pf Prism Cv in 2002.
Approval Date:
Vfend was approved by FDA for market use on 24 May, 2002.
Active Ingredient:
Vfend uses Voriconazole as the active ingredient. Check out other Drugs and Companies using Voriconazole ingredient
Treatment:
Vfend is used for treating fungal infections.
Dosage:
Vfend is available in the following dosage forms - for suspension form for oral use, tablet form for oral use, injectable form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 200MG/VIAL | INJECTABLE | Prescription | INTRAVENOUS |
| 50MG | TABLET | Prescription | ORAL |
| 200MG | TABLET | Prescription | ORAL |
| 200MG/5ML | FOR SUSPENSION | Prescription | ORAL |